CTI BioPharma's market cap is currently ―. The company's EPS TTM is $-0.846; its P/E ratio is -5.16; CTI BioPharma is scheduled to report earnings on May 4, 2023, and the estimated EPS forecast is $-0.10. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
Income Statement	-
Total Revenue	-	$ 18.24M	$ 12.33M	$ 2.29M	$ 0.00
Gross Profit	-	$ 17.09M	$ 11.41M	$ 2.02M	-
EBIT	-	$ -11.71M	$ -18.68M	$ -35.10M	$ -35.37M
EBITDA	-	$ -11.17M	$ -18.11M	$ -34.78M	$ -35.24M
Net Income Common Stockholders	-	$ -15.71M	$ -22.65M	$ -37.17M	$ -36.79M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 0.00	$ 81.64M	$ 95.87M	$ 96.90M	$ 65.45M
Total Assets	-	$ 123.47M	$ 134.53M	$ 131.44M	$ 72.43M
Total Debt	$ 0.00	$ 49.24M	$ 49.30M	$ 48.34M	$ 50.56M
Net Debt	$ 0.00	$ -32.40M	$ -46.57M	$ -48.56M	$ -14.89M
Total Liabilities	-	$ 140.30M	$ 139.81M	$ 159.35M	$ 68.67M
Stockholders Equity	$ 0.00	$ -16.84M	$ -5.27M	$ -27.92M	$ 3.77M
Cash Flow	-
Free Cash Flow	-	$ -40.46M	$ -20.24M	$ -29.98M	$ -30.02M
Operating Cash Flow	-	$ -15.46M	$ -20.24M	$ -29.98M	$ -30.02M
Investing Cash Flow	-	$ -19.60M	$ -54.79M	$ 0.00	$ 0.00
Financing Cash Flow	-	$ 1.02M	$ 44.22M	$ 61.43M	$ 188.00K

Currency in USD

CTI BioPharma Earnings and Revenue History

Income Statement >

CTI BioPharma Debt to Assets

Balance Sheet >

CTI BioPharma Cash Flow

Cash Flow >

CTI BioPharma Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing